CDK4/6 Inhibitor Drugs Industry - Regional Synopsis
North American Market Forecasts
North America industry is poised to account for largest revenue share of 69% by 2037. Increasing number of clinical trials in the region is also driving market growth. The NCI-sponsored TAILORx clinical trial focused on patients with ER-positive, node-negative breast cancer and found that a test that looks at the expression of certain genes can predict which women can safely avoid chemotherapy. Other studies, such as RxPONDER, have found that some postmenopausal women with HER-2-negative, HR-positive breast cancer that has spread to multiple lymph nodes and has a low risk of recurrence do not benefit from chemotherapy. As a result, the demand for targeted therapies has increased significantly in the United States.
European Market Statistics
The CDK4/6 inhibitor drugs market in the Europe region is anticipated to grow significantly by the end of 2037. The European CDK-4/6 inhibitors market is growing significantly due to increasing government initiatives in major European countries such as the UK, Germany, Spain, and France. Additionally, the increasing prevalence of breast cancer has increased the use of advanced treatments and drugs, which is also one of the key factors driving the growth of the CDK-4/6 inhibitors market. Breast cancer accounts for 13.3% of all new cancer cases and is estimated to affect 1 in 11 of 74-year-old women in the EU.
